KPV: The α-MSH Tripeptide That Kept the Anti-Inflammatory Half

KPV is three amino acids: lysine, proline and valine. Its formula is C16H30N4O4 and it weighs about 342 g/mol, which makes it one of the smallest molecules that can still reasonably be called a peptide. There is no cyclisation, no unusual residue and no protecting group.

Its interest comes entirely from provenance. α-melanocyte-stimulating hormone is a thirteen-residue peptide hormone with the sequence SYSMEHFRWGKPV, and KPV is its last three residues - positions 11, 12 and 13. The fragment is therefore sometimes written α-MSH(11–13), and that notation appears in the literature more often than the bare three-letter form.

One detail is worth flagging because it varies between papers. Within intact α-MSH the C-terminal valine is amidated. The free tripeptide catalogued here is the free-acid form, consistent with a mass of 342.4 g/mol; some published work instead uses the amidated variant, KPV-NH2. These are not the same molecule, and comparisons across studies should check which form was used.

The reason KPV exists as a research tool is subtractive. Melanocortin receptor binding - and with it the pigmentary signalling that gives α-MSH its name - depends principally on the core His-Phe-Arg-Trp motif at positions 6 through 9. That sequence is the melanocortin pharmacophore, and it is the part that engages MC1R on melanocytes to drive melanogenesis.

KPV does not contain it. Cutting the hormone back to its final three residues discards the pharmacophore entirely while retaining a C-terminal region that the literature associates with anti-inflammatory activity. The result is a fragment that appears to keep one of the parent hormone's functional arms and drop the other, and Brzoska and colleagues frame this dissociation as the substantive finding rather than a curiosity.

This is a genuinely useful property for dissecting mechanism. If a molecule reduces inflammatory signalling without the sequence required for classical melanocortin receptor engagement, then either the anti-inflammatory effect runs through a different route, or melanocortin receptors are being engaged in some non-classical way. Both possibilities are more informative than the parent hormone, where the two activities are confounded.

It also means the two families of α-MSH-derived agents should not be conflated. Clinical melanocortin drugs that do exist are built around retaining and stabilising the pharmacophore, which is the opposite design decision to the one KPV represents.

The pathway most consistently reported for KPV is nuclear factor κB. NF-κB is the transcriptional hub through which epithelial and immune cells convert inflammatory stimuli - bacterial products, TNF-α, IL-1β - into transcription of cytokines, chemokines and adhesion molecules. Held inactive in the cytoplasm by inhibitory IκB proteins, it translocates to the nucleus once those inhibitors are degraded.

Across cell models, KPV is reported to blunt this sequence, with reduced pathway activation and correspondingly lower output of downstream inflammatory mediators. In Dalmasso's intestinal epithelial work the suppression of NF-κB signalling is the readout that connects transporter-mediated entry to a functional consequence inside the cell.

What is not settled is what KPV binds to in order to produce that effect. Elliott and colleagues compared α-MSH, KPV and ACTH signalling in human keratinocytes and found KPV did not reproduce the classical melanocortin-receptor behaviour of the parent hormone, which argues against a straightforward MC1R-mediated explanation. The commonly used description - that KPV acts intracellularly and receptor-independently on NF-κB - is a reasonable reading of the available data, but it is a characterisation of where the effect is not coming from more than a positive identification of a molecular target.

That is an honest gap. Compared with the exemplary case where a peptide's effects are traced to a named receptor, KPV has a well-described pathway output and an unresolved proximal target.

Most of the substantive KPV work concerns intestinal inflammation, and the reason is a transporter. PepT1, encoded by SLC15A1, is a proton-coupled oligopeptide transporter that carries di- and tripeptides across the apical membrane of epithelial cells. Dalmasso and colleagues identified it as the route by which KPV enters intestinal epithelium, and showed that uptake through this channel let the tripeptide act at concentrations well below what unassisted permeation would demand.

The location of PepT1 makes this more than a delivery detail. In healthy tissue the transporter is characteristically small-intestinal, with limited colonic expression; under inflammatory conditions colonic epithelium expresses it. A molecule whose entry depends on PepT1 therefore has an access profile that shifts with the inflammatory state of the tissue - a self-selecting mechanism that is unusual and that explains the concentration of KPV research in colitis models.

Viennois and colleagues later complicated the picture. Working in a murine colitis-associated cancer model, they reported that PepT1 itself contributes to disease progression, while simultaneously being the transporter through which KPV acts. A mechanism that depends on an element that is not itself benign in the model system is worth noting plainly rather than smoothing over.

Every result described in this section is from cultured cells or mice. The colitis models used - chemically induced murine colitis and its cancer-associated variants - are standard preclinical tools, and standing alone they do not establish behaviour in human disease.

There are no published human clinical trials of KPV. This is the most important thing to state clearly, because the parent hormone and the broader melanocortin field have both attracted clinical attention, and it is easy for that adjacent activity to be read as evidence for the tripeptide. The indexed literature for KPV specifically is in vitro and rodent work.

Human pharmacokinetics are correspondingly absent. No published study characterises absorption, distribution, half-life or clearance of KPV in people. A tripeptide with unmodified termini is an obvious substrate for peptidase activity, and PepT1 expression varies with tissue and disease state, so exposure would be expected to depend heavily on context - but the shape of that dependence is not documented.

The target question also remains open in a way that limits interpretation. Without an identified binding partner, it is difficult to predict off-target behaviour, to reason about selectivity, or to anticipate what happens outside the epithelial and immune cell types that have been examined. Reviews in this area have been forthright that the field's future-clinical framing is prospective, and reading it as anything more concrete than that is not supported by what has been published.